| MLČOCHOVÁ, Jitka, Petra VYCHYTILOVÁ, Manuela FERRACIN, Barbara ZAGATTI, Lenka RADOVÁ, Marek SVOBODA, Radim NĚMEČEK, Stanislav JOHN, Igor KISS, Rostislav VYZULA, Massimo NEGRINI a Ondřej SLABÝ. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. Oncotarget. Albany: Impact Journals, 2015, roč. 6, č. 36, s. 38695-38704. ISSN 1949-2553. Dostupné z: https://dx.doi.org/10.18632/oncotarget.5735. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1314693,
author = {Mlčochová, Jitka and Vychytilová, Petra and Ferracin, Manuela and Zagatti, Barbara and Radová, Lenka and Svoboda, Marek and Němeček, Radim and John, Stanislav and Kiss, Igor and Vyzula, Rostislav and Negrini, Massimo and Slabý, Ondřej},
article_location = {Albany},
article_number = {36},
doi = {http://dx.doi.org/10.18632/oncotarget.5735},
keywords = {microRNA; colorectal cancer; cetuximab; miR-31; progression},
language = {eng},
issn = {1949-2553},
journal = {Oncotarget},
title = {MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab},
url = {http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=5735&pubmed-linkout=1},
volume = {6},
year = {2015}
}
TY - JOUR
ID - 1314693
AU - Mlčochová, Jitka - Vychytilová, Petra - Ferracin, Manuela - Zagatti, Barbara - Radová, Lenka - Svoboda, Marek - Němeček, Radim - John, Stanislav - Kiss, Igor - Vyzula, Rostislav - Negrini, Massimo - Slabý, Ondřej
PY - 2015
TI - MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab
JF - Oncotarget
VL - 6
IS - 36
SP - 38695-38704
EP - 38695-38704
PB - Impact Journals
SN - 19492553
KW - microRNA
KW - colorectal cancer
KW - cetuximab
KW - miR-31
KW - progression
UR - http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=5735&pubmed-linkout=1
L2 - http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=5735&pubmed-linkout=1
N2 - The aim of our study was to investigate whether microRNAs (miRNAs) could serve as predictive biomarkers to anti-EGFR therapy (cetuximab, panitumumab) in patients with RAS wild-type (wt-RAS) metastatic colorectal cancer (mCRC). Historical cohort of 93 patiens with mCRC (2006–2009) was included and further divided into exploratory and validation cohorts. MiRNAs expression profiling was performed on the exploratory cohort of 41 wt-KRAS mCRC patients treated with cetuximab to identify miRNAs associated with time to progression (TTP). The validation was performed on two independent cohorts: 28 patients of wt-RAS mCRC treated with cetuximab and 24 patients of wt-RAS mCRC treated with panitumumab. We identified 9 miRNAs with significantly different expression between responders and non-responders to cetuximab therapy (P < 0.01). These 9 miRNAs were further evaluated in two independent cohorts of patients and miR-31-3p (P < 0.001) and miR-31-5p (P < 0.001) were sucessfully confirmed as strongly associated with TTP in wt-RAS mCRC patients treated with cetuximab but not panitumumab. When evaluated on the complete cohort of cetuximab patients (N = 69), miR-31-3p (HR, 5.10; 95% CI, 2.52–10.32; P < 0.001) and miR-31-5p (HR, 4.80; 95% CI, 2.50–9.24; P < 0.001) were correlated with TTP on the comparable level of significance. There was no difference in miR-31-5p/3p expression levels in RAS mutated and wild-type tumor samples. MiR-31-5p/3p are promising predictive biomarkers of cetuximab response in wt-RAS mCRC patients.
ER -
MLČOCHOVÁ, Jitka, Petra VYCHYTILOVÁ, Manuela FERRACIN, Barbara ZAGATTI, Lenka RADOVÁ, Marek SVOBODA, Radim NĚMEČEK, Stanislav JOHN, Igor KISS, Rostislav VYZULA, Massimo NEGRINI a Ondřej SLABÝ. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab. \textit{Oncotarget}. Albany: Impact Journals, 2015, roč.~6, č.~36, s.~38695-38704. ISSN~1949-2553. Dostupné z: https://dx.doi.org/10.18632/oncotarget.5735.
|
